References:
1. Starzl TE, Fung JJ. Themes of liver transplantation.HEPATOLOGY (2010) 51 : 1869-1884.
2. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. AM J TRANSPLANT (2010)10 : 1420-1427.
3. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl (2011) 17 Suppl 3 : S1-S9.
4. Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA et al . OPTN/SRTR 2019 Annual Data Report: Liver. AM J TRANSPLANT (2021)21 Suppl 2 : 208-315.
5. Rana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H et al . No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. ANN SURG (2019) 269 : 20-27.
6. Aberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen Aet al . Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study.HEPATOLOGY (2015) 61 : 668-677.
7. Mukherjee S, Mukherjee U. A Comprehensive Review of Immunosuppression Used for Liver Transplantation. Journal of Transplantation (2009)2009 : 1-20.
8. Tasdogan BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on Immunosuppression in Liver Transplantation. Euroasian J Hepatogastroenterol (2019)9 : 96-101.
9. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. AM J TRANSPLANT (2006)6 : 1578-1585.
10. Pflugrad H, Schrader AK, Tryc AB, Ding X, Lanfermann H, Jackel Eet al . Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation. Liver Transpl (2018)24 : 56-66.
11. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.Cochrane Database Syst Rev (2017) 3 : D11639.
12. Beresford T. Neuropsychiatric complications of liver and other solid organ transplantation. LIVER TRANSPLANT (2001) 7 : S36-S45.
13. Pruitt A. Neurological complications after solid organ transplantation. J NEUROL SCI (2015) 357 : e483.
14. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee Wet al . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. CLIN PHARMACOL THER (2015) 98 : 19-24.
15. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T et al . Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. CLIN PHARMACOL THER (2006) 80 : 331-345.
16. Staatz CE, Tett SE. Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. Adis International: Cham 2004:623-653.
17. de Wildt SN, van Schaik RHN, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP et al . The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. EUR J CLIN PHARMACOL (2011) 67 : 1231-1241.
18. Calvo PL, Serpe L, Brunati A, Nonnato A, Bongioanni D, Olio DD et al . DonorCYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. BRIT J CLIN PHARMACO(2017) 83 : 1252-1262.
19. Buendía JA, Halac E, Bosaleh A, Garcia De Davila MT, Imvertasa O, Bramuglia G. Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation.PHARMACEUTICS (2020) 12 : 898.
20. Th Rn M, Lundgren S, Herlenius G, Ericzon BR, L F L, Rane A. Gene expression of cytochromes P 450 in liver transplants over time.EUR J CLIN PHARMACOL (2004) 60 .
21. Ince I, Knibbe CAJ, Danhof M, de Wildt SN. Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo Investigations. CLIN PHARMACOKINET(2013) 52 : 333-345.
Table 1. Comparison between CsA and TAC